Weaver C. Barksdale & Associates Inc. maintained its position in Medtronic PLC (NYSE:MDT) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,833 shares of the medical technology company’s stock at the close of the 2nd quarter. Weaver C. Barksdale & Associates Inc.’s holdings in Medtronic PLC were worth $961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Medtronic PLC by 0.3% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 2,920 shares of the medical technology company’s stock valued at $235,000 after purchasing an additional 9 shares during the period. Triangle Securities Wealth Management boosted its stake in shares of Medtronic PLC by 0.3% during the second quarter. Triangle Securities Wealth Management now owns 4,396 shares of the medical technology company’s stock valued at $390,000 after purchasing an additional 15 shares during the period. Tarbox Group Inc. boosted its stake in shares of Medtronic PLC by 0.4% during the first quarter. Tarbox Group Inc. now owns 5,180 shares of the medical technology company’s stock valued at $417,000 after purchasing an additional 20 shares during the period. Shufro Rose & Co. LLC boosted its stake in shares of Medtronic PLC by 0.3% during the first quarter. Shufro Rose & Co. LLC now owns 10,381 shares of the medical technology company’s stock valued at $836,000 after purchasing an additional 28 shares during the period. Finally, Guardian Life Insurance Co. of America boosted its stake in shares of Medtronic PLC by 0.6% during the first quarter. Guardian Life Insurance Co. of America now owns 5,288 shares of the medical technology company’s stock valued at $426,000 after purchasing an additional 29 shares during the period. 80.62% of the stock is owned by hedge funds and other institutional investors.

MDT has been the subject of a number of analyst reports. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $93.00 price objective (up previously from $87.00) on shares of Medtronic PLC in a research note on Thursday, May 25th. Needham & Company LLC reissued a “buy” rating and set a $95.00 price objective (up previously from $91.00) on shares of Medtronic PLC in a research note on Thursday, May 25th. CIBC reissued a “buy” rating on shares of Medtronic PLC in a research note on Friday, May 26th. Evercore ISI reissued an “outperform” rating and set a $91.00 price objective (up previously from $88.50) on shares of Medtronic PLC in a research note on Sunday, May 28th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $91.00 price objective (up previously from $84.00) on shares of Medtronic PLC in a research note on Sunday, May 28th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $88.78.

WARNING: “Weaver C. Barksdale & Associates Inc. Maintains Holdings in Medtronic PLC (MDT)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/22/weaver-c-barksdale-associates-inc-maintains-holdings-in-medtronic-plc-mdt.html.

Shares of Medtronic PLC (MDT) traded up 0.39% during trading on Friday, hitting $79.84. The stock had a trading volume of 2,149,398 shares. The stock has a 50-day moving average price of $82.04 and a 200 day moving average price of $83.67. Medtronic PLC has a 12 month low of $69.35 and a 12 month high of $89.72. The company has a market cap of $108.15 billion, a P/E ratio of 26.87 and a beta of 1.03.

Medtronic PLC (NYSE:MDT) last issued its earnings results on Tuesday, August 22nd. The medical technology company reported $1.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.04. Medtronic PLC had a return on equity of 12.92% and a net margin of 13.75%. The business had revenue of $7.39 billion during the quarter, compared to analysts’ expectations of $7.44 billion. During the same period in the prior year, the business earned $1.03 EPS. The business’s revenue for the quarter was up 3.1% compared to the same quarter last year. Equities analysts expect that Medtronic PLC will post $4.77 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 29th will be issued a $0.46 dividend. This represents a $1.84 annualized dividend and a dividend yield of 2.30%. The ex-dividend date is Thursday, September 28th. Medtronic PLC’s dividend payout ratio is 61.95%.

In other Medtronic PLC news, EVP Bryan C. Hanson sold 12,000 shares of the company’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $88.57, for a total value of $1,062,840.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $81.63, for a total value of $11,461,423.41. Following the completion of the sale, the chief executive officer now owns 668,503 shares of the company’s stock, valued at $54,569,899.89. The disclosure for this sale can be found here. 0.31% of the stock is currently owned by corporate insiders.

Medtronic PLC Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic PLC (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.